Skip to content
GLP-1 Scorecard
Menu
Graded #229

Levity

Levity is a telehealth weight loss provider dispensing FDA-approved branded GLP-1 medications only, with no compounded options.

Visit LevityWe may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Semaglutide
$1,199/mo (all doses, bundle, brand-name)
Tirzepatide
$1,299/mo (all doses, bundle, brand-name)
Coverage
36 states
Brand-name
Yes

Weigh Levity against the full graded field on the best semaglutide providers scorecard, or line it up against its closest alternatives.

Factor breakdown

Each of the six graded dimensions. See the methodology.

Cost value31/100
Dose & formulation85/100
Clinical oversight87/100
Labs & monitoring64/100
Fulfillment77/100
Contract terms53/100

Strengths

  • FDA-approved branded Mounjaro, Wegovy, and Ozempic only
  • All-inclusive fee covers Rx, consult, shipping, and support
  • LegitScript verified with named pharmacy and physician leads
  • Available across 34 states with unlimited clinical support

Where it loses points

  • Premium pricing, roughly 1,199 to 1,599 per month
  • No compounded lower-cost alternatives
  • Support hours limited to weekday business hours
  • Bundled fee may exceed insurance-covered branded options

Bottom line — Grade C

Best for: Patients wanting all-inclusive branded GLP-1 pens and willing to pay premium cash prices.

Ranked #229 of 499 on this scorecard. See our top-scoring pick, CoreAge Rx (#1), for comparison.

Closest on the board

The boards grading nearest Levity — the realistic shortlist.

The 21 boards nearest this one

View full scorecard rankings →

Pricing/verification reflect Levity's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on Levity's site. Not medical advice; see our disclosure.

← Back to the scorecard